Accolade Stock Price, News & Analysis (NASDAQ:ACCD) $9.14 +0.08 (+0.88%) (As of 12/4/2023 ET) Add Compare Share Share Today's Range$8.81▼$9.2050-Day Range$6.50▼$10.7652-Week Range$6.33▼$17.00Volume616,806 shsAverage Volume628,072 shsMarket Capitalization$696.76 millionP/E RatioN/ADividend YieldN/APrice Target$15.14 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaSustainability Accolade MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.69 Rating ScoreUpside/Downside65.7% Upside$15.14 Price TargetShort InterestHealthy4.11% of Shares Sold ShortDividend StrengthN/ASustainability-0.89Upright™ Environmental ScoreNews SentimentN/AInsider TradingSelling Shares$74,397 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($1.56) to ($1.38) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.67 out of 5 starsBusiness Services Sector37th out of 301 stocksBusiness Services, Not Elsewhere Classified Industry12th out of 85 stocks 4.3 Analyst's Opinion Consensus RatingAccolade has received a consensus rating of Moderate Buy. The company's average rating score is 2.69, and is based on 9 buy ratings, 4 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $15.14, Accolade has a forecasted upside of 65.7% from its current price of $9.14.Amount of Analyst CoverageAccolade has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 3.0 Short Interest Percentage of Shares Shorted4.11% of the outstanding shares of Accolade have been sold short.Short Interest Ratio / Days to CoverAccolade has a short interest ratio ("days to cover") of 5.4.Change versus previous monthShort interest in Accolade has recently decreased by 2.19%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldAccolade does not currently pay a dividend.Dividend GrowthAccolade does not have a long track record of dividend growth. Previous Next 4.8 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreAccolade has received a 76.67% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Private oncologist's appointments", "Private neurologist's appointments", "Private general practice doctor's diagnostic online appointments", "Private cardiologist's online appointments", and "Private gynaecologist's online appointments" products. See details.Environmental SustainabilityThe Environmental Impact score for Accolade is -0.89. Previous Next 2.1 News and Social Media Coverage News SentimentAccolade has a news sentiment score of 0.83. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.64 average news sentiment score of Business Services companies.News Coverage This WeekMarketBeat has tracked 1 news article for Accolade this week, compared to 2 articles on an average week.Search InterestOnly 1 people have searched for ACCD on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Accolade insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $74,397.00 in company stock.Percentage Held by InsidersOnly 8.30% of the stock of Accolade is held by insiders.Percentage Held by Institutions73.92% of the stock of Accolade is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Accolade are expected to grow in the coming year, from ($1.56) to ($1.38) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Accolade is -4.74, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Accolade is -4.74, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAccolade has a P/B Ratio of 1.40. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Accolade Stock (NASDAQ:ACCD)Accolade, Inc., together with its subsidiaries, engages in the development and provision of personalized and technology-enabled solutions that help people to understand, navigate, and utilize the healthcare system and their workplace benefits in the United States. The company offers a platform with cloud-based technology and multimodal support from a team of health assistants and clinicians, including registered nurses, physician medical directors, pharmacists, behavioral health specialists, women's health specialists, case management specialists, expert medical opinion providers, and virtual primary care physicians. It also provides medical opinion and decision support services; and technology and administrative services to the medical practice PCs providing virtual primary care services. The company serves employers who provide their employees and their employees' families a single place to turn for their health, healthcare, and benefits needs. Accolade, Inc. was incorporated in 2007 and is headquartered in Seattle, Washington.Read More ACCD Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ACCD Stock News HeadlinesDecember 4, 2023 | americanbankingnews.comAccolade, Inc. (NASDAQ:ACCD) Receives Consensus Recommendation of "Moderate Buy" from AnalystsNovember 27, 2023 | finance.yahoo.comAccolade To Present at Piper Sandler 35th Annual Healthcare ConferenceDecember 4, 2023 | Wealthpress (Ad)Trading Experts Call It “The Perfect Tesla Trade”Thanks to a new discovery linked to shares of Tesla, regular folks can now target gains of 100% or more in six days or less. New research shows it’s happened 23 different times this year. The next trade is scheduled for this Thursday.November 22, 2023 | markets.businessinsider.comExpert Ratings for AccoladeNovember 16, 2023 | finance.yahoo.comAccolade Announces Repurchase of $76.5 Million of 0.50% Convertible Senior Notes Due 2026November 8, 2023 | finance.yahoo.comAccolade To Present at Stephens Annual Investment ConferenceNovember 5, 2023 | morningstar.comAccolade Inc Ordinary Shares ACCDNovember 2, 2023 | finance.yahoo.comDown -31.39% in 4 Weeks, Here's Why Accolade (ACCD) Looks Ripe for a TurnaroundDecember 4, 2023 | Wealthpress (Ad)Trading Experts Call It “The Perfect Tesla Trade”Thanks to a new discovery linked to shares of Tesla, regular folks can now target gains of 100% or more in six days or less. New research shows it’s happened 23 different times this year. The next trade is scheduled for this Thursday.October 19, 2023 | msn.comAccolade: Multiples Should Rerate As ACCD Continues To ExecuteOctober 11, 2023 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Affimed (AFMD) and Accolade (ACCD)October 11, 2023 | msn.comObesity drug coverage among U.S. employers to nearly double in 2024: surveyOctober 11, 2023 | markets.businessinsider.comCautious Outlook on Accolade’s Future Growth and Valuation: An Analysis of Stan Berenshteyn’s Hold RatingOctober 10, 2023 | markets.businessinsider.comProjected Rise in GLP-1 Coverage by Employers and its Potential Impact on Accolade’s Membership Rates and Health Insurance CostsOctober 9, 2023 | msn.comU.S. employers covering weight-loss drugs could nearly double in 2024 - surveyOctober 9, 2023 | finance.yahoo.comGLP-1 Coverage in Employer Plans Could Nearly Double in 2024October 9, 2023 | finance.yahoo.comHere's Why Accolade (ACCD) is Poised for a Turnaround After Losing -36.43% in 4 WeeksOctober 7, 2023 | msn.comWhy Shares of Accolade Fell This WeekOctober 5, 2023 | markets.businessinsider.comAccolade (ACCD) Gets a Buy from D.A. DavidsonOctober 5, 2023 | markets.businessinsider.comRaymond James Maintains Outperform Rating for Accolade: Here's What You Need To KnowOctober 5, 2023 | finanznachrichten.deAccolade, Inc.: Accolade Announces Results for Fiscal Second Quarter 2024October 5, 2023 | markets.businessinsider.comAccolade’s Robust Performance and Steady Financial Outlook: A Comprehensive Analysis for a Buy RatingOctober 5, 2023 | finance.yahoo.comAccolade, Inc. (NASDAQ:ACCD) Q2 2024 Earnings Call TranscriptOctober 4, 2023 | markets.businessinsider.comAccolade Announces Results for Fiscal Second Quarter 2024October 4, 2023 | markets.businessinsider.comWhy Accolade Stock Is Falling After-HoursOctober 4, 2023 | finance.yahoo.comAccolade Inc (ACCD) Reports Strong Q2 2024 Earnings, Exceeds Top and Bottom Line GuidanceOctober 4, 2023 | msn.comLevi CEO fires over half of execs, says should have fired “the wrong people” even fasterSee More Headlines Receive ACCD Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Accolade and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings10/04/2023Today12/04/2023Next Earnings (Estimated)1/08/2024Fiscal Year End2/29/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Business services, not elsewhere classified Sub-IndustryN/A SectorBusiness Services Current SymbolNASDAQ:ACCD CUSIPN/A CIK1481646 Webaccolade.com Phone206-926-8100FaxN/AEmployees2,370Year FoundedN/APrice Target and Rating Average Stock Price Target$15.14 High Stock Price Target$19.00 Low Stock Price Target$10.00 Potential Upside/Downside+65.7%Consensus RatingModerate Buy Rating Score (0-4)2.69 Research Coverage13 Analysts Profitability EPS (Most Recent Fiscal Year)($1.93) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-459,650,000.00 Net Margins-37.24% Pretax Margin-37.19% Return on Equity-30.58% Return on Assets-15.96% Debt Debt-to-Equity Ratio0.65 Current Ratio3.08 Quick Ratio3.08 Sales & Book Value Annual Sales$380.06 million Price / Sales1.83 Cash FlowN/A Price / Cash FlowN/A Book Value$6.51 per share Price / Book1.40Miscellaneous Outstanding Shares76,232,000Free Float69,905,000Market Cap$696.76 million OptionableNot Optionable Beta2.06 7 Energy Stocks to Buy and Hold ForeverDo you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.Get This Free Report Key ExecutivesMr. Rajeev Singh (Age 55)Chairman of the Board & CEO Comp: $778.5kMr. Robert Cavanaugh (Age 54)President Comp: $582.63kMr. Stephen H. Barnes CPA (Age 51)CFO & Treasurer Comp: $557.5kMs. Kristen BruzekSenior Vice President of OperationsMr. Colin McHugh (Age 44)Chief Accounting Officer Mr. Todd FriedmanSenior Vice President of Investor RelationsMr. Richard Eskew (Age 48)Executive VP, General Counsel, CCO & Secretary Ms. Jennifer HansonExecutive VP & Chief Human Resource OfficerMr. Drew GarnerExecutive Vice President of EngineeringDr. Shantanu Nundy M.B.A.M.D., Executive VP of Care Delivery, Chief Health Officer & Member of the Medical Advisory BoardMore ExecutivesKey CompetitorsConduentNASDAQ:CNDTMediaAlphaNYSE:MAXPaysafeNYSE:PSFELiquidity ServicesNASDAQ:LQDTViadNYSE:VVIView All CompetitorsInsiders & InstitutionsAmerican Century Companies Inc.Sold 6,089 shares on 11/30/2023Ownership: 0.028%Deutsche Bank AGSold 90,642 shares on 11/24/2023Ownership: 0.260%Walleye Trading LLCSold 300 shares on 11/21/2023Ownership: 0.000%Rajeev SinghSold 358 sharesTotal: $2,842.52 ($7.94/share)Robert N CavanaughSold 149 sharesTotal: $1,183.06 ($7.94/share)View All Insider TransactionsView All Institutional Transactions ACCD Stock Analysis - Frequently Asked Questions Should I buy or sell Accolade stock right now? 13 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Accolade in the last year. There are currently 4 hold ratings and 9 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" ACCD shares. View ACCD analyst ratings or view top-rated stocks. What is Accolade's stock price target for 2024? 13 brokers have issued twelve-month price targets for Accolade's stock. Their ACCD share price targets range from $10.00 to $19.00. On average, they expect the company's share price to reach $15.14 in the next year. This suggests a possible upside of 65.7% from the stock's current price. View analysts price targets for ACCD or view top-rated stocks among Wall Street analysts. How have ACCD shares performed in 2023? Accolade's stock was trading at $7.79 at the start of the year. Since then, ACCD shares have increased by 17.3% and is now trading at $9.14. View the best growth stocks for 2023 here. When is Accolade's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, January 8th 2024. View our ACCD earnings forecast. How were Accolade's earnings last quarter? Accolade, Inc. (NASDAQ:ACCD) announced its quarterly earnings results on Wednesday, October, 4th. The company reported ($0.43) EPS for the quarter, beating analysts' consensus estimates of ($0.54) by $0.11. The business earned $96.86 million during the quarter, compared to the consensus estimate of $94.09 million. Accolade had a negative trailing twelve-month return on equity of 30.58% and a negative net margin of 37.24%. The business's revenue for the quarter was up 10.5% compared to the same quarter last year. During the same period in the prior year, the firm posted ($0.66) earnings per share. What ETFs hold Accolade's stock? ETFs with the largest weight of Accolade (NASDAQ:ACCD) stock in their portfolio include ARK Genomic Revolution ETF (ARKG), SPDR S&P Health Care Services ETF (XHS), Invesco Dorsey Wright Healthcare Momentum ETF (PTH) and First Trust Nasdaq Lux Digital Health Solutions ETF (EKG).iShares U.S. Healthcare Providers ETF (IHF). What guidance has Accolade issued on next quarter's earnings? Accolade updated its third quarter 2024 earnings guidance on Wednesday, October, 4th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $95.00 million-$97.00 million, compared to the consensus revenue estimate of $96.57 million. What is Rajeev Singh's approval rating as Accolade's CEO? 152 employees have rated Accolade Chief Executive Officer Rajeev Singh on Glassdoor.com. Rajeev Singh has an approval rating of 74% among the company's employees. What other stocks do shareholders of Accolade own? Based on aggregate information from My MarketBeat watchlists, some companies that other Accolade investors own include CVS Health (CVS), Johnson & Johnson (JNJ), RTX (RTX), Alibaba Group (BABA), Home Depot (HD), Procter & Gamble (PG), Thermo Fisher Scientific (TMO), Cisco Systems (CSCO) and Intel (INTC). When did Accolade IPO? (ACCD) raised $176 million in an initial public offering (IPO) on Thursday, July 2nd 2020. The company issued 8,800,000 shares at a price of $19.00-$21.00 per share. Goldman Sachs, Morgan Stanley and BofA Securities acted as the underwriters for the IPO and Piper Sandler, Credit Suisse, William Blair, Baird and SVB Leerink were co-managers. Who are Accolade's major shareholders? Accolade's stock is owned by many different institutional and retail investors. Top institutional investors include JPMorgan Chase & Co. (8.63%), Brown Advisory Inc. (7.96%), ARK Investment Management LLC (7.93%), Rock Springs Capital Management LP (3.82%), Sumitomo Mitsui Trust Holdings Inc. (2.36%) and Northern Trust Corp (0.97%). Insiders that own company stock include Colin Mchugh, Michael W Hilton, Rajeev Singh, Richard Eskew, Robert N Cavanaugh, Stephen H Barnes and Thomas J Neff. View institutional ownership trends. How do I buy shares of Accolade? Shares of ACCD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. This page (NASDAQ:ACCD) was last updated on 12/4/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Accolade, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.